MedImmune and Micromet enter agreement to co-develop treatment for B cell tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      MEDIMMUNE Inc. 190639906 MEDI; MICROMET Inc.
    • Abstract:
      Reports that MedImmune and Micromet entered into an agreement to co-develop Micromet's treatment for B cell tumors, MT103, a representative of a novel class of antibody derivatives called Bi-Specific T Cell Engagers (BiTE). Agreement to create six novel drug candidates using Micromet's proprietary BiTE; European phase I studies of MT103 initiated by Micromet.